big pharma

Lilly Caves, Agrees To Add Warnings To Schizophrenia Drug

Lilly Caves, Agrees To Add Warnings To Schizophrenia Drug

Zyprexa, Lilly’s best-selling drug to treat schizophrenia, has been shown to cause “cause weight gain, high blood sugar, high cholesterol and other metabolic problems,” but until now, the company has refused to add any warnings about these side effects to the label. Now, sparked in part by lower sales, Lilly has announced that Zyprexa will warn consumers that it can cause high blood sugar. The American Diabetes Association claims that Zyprexa causes diabetes, but this isn’t addressed on the new warning labels.

Liveblogging The House Energy And Commerce Committee Hearing On Food Safety

Liveblogging The House Energy And Commerce Committee Hearing On Food Safety

Starting today at 10 a.m., the powerful Chairman of the House Energy and Commerce Committee, John Dingell (D-MI), will hold a hearing on H.R. 3610, The Food and Drug Import Safety Act of 2007, or, as we have dubbed the bill, The Poison-Free Food Act. The bill would dramatically alter the FDA’s handling of imported foods, empowering the agency to:

  • Issue mandatory recalls;
  • Limit food imports to ports clustered near FDA inspection labs;
  • Require a country of origin labels for food, drugs and medical devices;
  • Subject exporters to a strict certification program administered by the Department of Health and Human Services.

The Committee will hear from two panels: The first will see FDA Commissioners and regulators defending their agency, while the second will host a panoply of foodies, including the Coalition for a Stronger FDA, the Center for Science in the Public Interest, the Grocery Manufacturers Association, and Big Pharma.

Avandia Stays On The Market

Since the study was published, Consumer Reports has come out in favor of older drugs:

Diabetes drugs received wide attention last spring when research found a possible link between rosiglitazone (Avandia) and a higher risk of heart attacks. While those risks remain unclear, the CR Best Buy Drug report cites other reasons that rosiglitazone and the related drug pioglitazone (Actos) are not wise first choices for most people with diabetes, including their higher risk of heart failure compared with other diabetes drugs.

Consumer Reports that patients should first ask their doctors about metformin (Glucophage and generic), claiming that the effectiveness of the older drugs are equivalent to the newer ones, but with less potential risk.